Eris Lifesciences Limited has informed the Exchange regarding Board meeting held on Jun 30, 2025.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Smallcap 250 and 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences' board, at its meeting on June 30, 2025, approved the re-appointment of four key directors for 5-year terms: Managing Director Amit Indubhushan Bakshi (from April 1, 2026) and Whole Time Directors Inderjeet Singh Negi, Kaushal Kamlesh Shah, and Krishnakumar Vaidyanathan (staggered start dates between October 2025 and September 2026). The board also recommended appointing Walker Chandiok & Co LLP as the new statutory auditor for 5 years, replacing Deloitte Haskins & Sells LLP whose term expires at the upcoming AGM. The 19th Annual General Meeting has been scheduled for July 25, 2025, where shareholders will vote on these proposals.
This is routine corporate governance signaling leadership continuity at the top. The auditor change is a standard rotation at the end of the existing auditor's term rather than a mid-term switch, which is generally seen as normal. No material impact on share price is expected from these items.